ObsEva SA
Quick facts
Phase 3 pipeline
- Add-back · Gynecology / Reproductive Health
Add-back is a progestin (norethisterone acetate) co-administered with a GnRH agonist to mitigate hypogonadal side effects while maintaining the therapeutic benefits of GnRH suppression. - OBE2109 · Gynecology / Reproductive Health
OBE2109 is a selective progesterone receptor modulator that modulates progesterone signaling to treat reproductive and gynecological disorders. - Placebo to match Add-back
This drug is a placebo used to match an add-back therapy. - Placebo to match OBE2109
This is a placebo formulation designed to match the appearance, taste, and administration characteristics of OBE2109 for blinded clinical trial purposes.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: